Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00218543 · ClinicalTrials.gov registry record · Phase 2
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 2 study of Cocaine-Related Disorders and Attention Deficit Disorder With Hyperactivity, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00218543: Completed Phase 2 study of Cocaine-Related Disorders and Attention Deficit Disorder With Hyperactivity, sponsored by New York State Psychiatric Institute.
NCT00218543 is a Phase 2 study of Cocaine-Related Disorders and Attention Deficit Disorder With Hyperactivity that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 20 participants, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00218543, a Phase 2 study of Cocaine-Related Disorders and Attention Deficit Disorder With Hyperactivity, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD. Rates of cocaine abuse in adults with ADHD are significantly higher than they are in adults who do not have ADHD. Some clinicians suggest that adults with ADHD may abuse cocaine in order to self-medicate their ADHD symptoms. Atomoxetine is a drug that has been effective in treating ADHD. This study will evaluate the effectiveness of atomoxetine in reducing cocaine use in people with ADHD who abuse cocaine.
Primary Outcome
AARS is a self report that measures symptoms of adult ADHD. The primary outcome was the percentage of patients achieving a 30% reduction from baseline on the AARS scale. The AARS is scored on a continuous, range 0-54. 0 being no symptoms and 54 being indicative of the most severe level of symptoms.
Conditions Studied
Interventions
- DRUG Atomoxetine
Study Locations (1)
New York
- Research Foundation for Mental Hygiene, Inc. - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00218543 record still lists
NCT00218543 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 64-participant average among 15 other Cocaine-Related Disorders trials with a reported enrollment target (69% lower).
The record links to 2 conditions, with Cocaine-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which Atomoxetine is the first listed.
NCT00218543 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00218543 about?
NCT00218543 is a clinical study titled "Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)". Studies have shown that individuals with attention deficit hyperactivity disorder (ADHD) are at greater risk for having a substance use disorder compared to people who do not have ADHD. Rates of cocaine abuse in adults with ADHD are significantly higher than they are in adults who do not have ADHD. ...
What is the current status of trial NCT00218543?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2004-06. Estimated completion is 2007-03.
What conditions does trial NCT00218543 study?
This clinical trial studies the following conditions: Cocaine-Related Disorders, Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT00218543?
The interventions under investigation include: Atomoxetine (DRUG).
Who is sponsoring clinical trial NCT00218543?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00218543 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cocaine-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00218543's enrollment target sits among peer trials
20 10th of 15 higher than 6 of 15 other Cocaine-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cocaine-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention
COMPLETED · Phase 2
-
Pharmacological Modulation of Cocaine Effects - 1
COMPLETED · Phase 2
-
Gepirone vs Placebo in Treatment of Cocaine Dependence - 3
COMPLETED · Phase 2
-
Risperidone Treatment in Dually-Diagnosed Individuals - 2
COMPLETED · Phase 2
-
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
COMPLETED · Phase 2
-
Evaluation of Benztropine for Cocaine Craving - 2
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia